Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate AMX-818 expected to enter the clinic in early ...
Read moreDetails
